On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation ...
Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.
Abstract: The goal of neural ISP is to convert the RAW data captured by camera sensors into display-referred sRGB images via an end-to-end neural network. Most methods are based on the regression, so ...
Pulmonary arterial hypertension (PAH) involves progressive cellular and molecular change within the pulmonary vasculature, leading to increased vascular resistance. Current therapies targeting nitric ...
Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other systemic complications.
The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with high GI and pulmonary involvement.
Diffuse cutaneous systemic sclerosis (“dcSSc”) is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for ...
Abstract: Accurately assessing mental states—such as mental workload and fatigue— is crucial for ensuring the reliability and effectiveness of brain-computer interface (BCI)-based applications.
Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing long-term disability outcomes in multiple sclerosis (MS). However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results